CD34+ Cell Therapy for the treatment of coronary microvascular dysfunction.

This project uses the patient’s own cells to repair and regenerate the damaged cardiovascular tissue in their coronary arteries. CLBS14 has been approved for a Phase 2 exploratory clinical trial in coronary microvascular dysfunction with financial support for the trial coming from a grant awarded by the National Heart, Lung and Blood Institute of the National Institutes of Health.

(B. Samuels, MD)